Shanghai Junshi Biosciences Co Ltd (Junshi Biotech) is a biopharmaceutical company that discovers, develops and commercialization of novel therapies. The company offers products for various diseases including tumor immunotherapy, autoimmune system diseases, chronic metabolic diseases, neurological diseases, and infectious diseases. Junshi Biotech products include toripalimab injection, adalimumab, Deuterated and etesevirumab. Its other pipelines include JS211, JS209, JS208, JS121, JS115, JS114, JS019 and others. It works in partnership with Coherus and Conlida for the development and commercialization of its products. The company operates its research and development centers in the US and China. Junshi Biotech is headquartered in Shanghai, China.
Headquarters
China
Address
16 Floor, Building 7, No. 6, Lane 100, Pingjiaqiao Road, Shanghai, 201203
Website
www.junshipharma.com
Telephone
86 21 61058800
No of Employees
2,568
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1877 (HKG)
Revenue (2022)
$212.4M
3.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
4.4%
(2022 vs 2021)
Market Cap*
$2.9B
Net Profit Margin (2022)
XYZ
7.5%
(2022 vs 2021)
* As of and is in US$
Shanghai Junshi Biosciences Co Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Toripalimab | Research and Development |
| Adalimumab | Therapies |
| Deuterated | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In April, the company secured approval from the National Medical Products Administration for toripalimab. |
| 2024 | Regulatory Approval | In February, the company received approval from the Singapore Health Sciences Authority for toripalimab for the initial treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. |
| 2024 | Contracts/Agreements | In January, the company entered into a Technology Development Contract with Shanghai Allink, under which Shanghai Allink undertook a research and development project for cell line development and production of drug substances and preparations. |
Competitor Comparison
| Key Parameters | Shanghai Junshi Biosciences Co Ltd | InnoCare Pharma Ltd | Sino Biological Inc | Ascletis Pharma Inc | China Pharma Holdings Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Beijing | Beijing | Hangzhou | Haikou |
| State/Province | Shanghai | Beijing | Beijing | Zhejiang | Hainan |
| No. of Employees | 2,568 | 1,072 | 913 | 219 | 231 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Xiong Jun | Chairman | Executive Board | 2018 | - |
| Li Ning | Vice Chairman | Executive Board | 2024 | 62 |
| Zhang Zhuobing | Director; Deputy General Manager | Executive Board | 2018 | - |
| Zou Jianjun | General Manager; Director | Executive Board | 2022 | - |
| Gang Wang | Director; Deputy General Manager | Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward